Eversept Partners LLC Purchases Shares of 33,500 Alexion Pharmaceuticals, Inc. (ALXN)

Eversept Partners LLC purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $4,006,000. Alexion Pharmaceuticals makes up 3.3% of Eversept Partners LLC’s investment portfolio, making the stock its 11th biggest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in ALXN. WINTON GROUP Ltd purchased a new position in Alexion Pharmaceuticals during the second quarter worth about $296,000. Robeco Institutional Asset Management B.V. grew its position in Alexion Pharmaceuticals by 7.7% during the third quarter. Robeco Institutional Asset Management B.V. now owns 10,605 shares of the biopharmaceutical company’s stock worth $1,489,000 after buying an additional 755 shares in the last quarter. Meeder Asset Management Inc. grew its position in Alexion Pharmaceuticals by 603.1% during the third quarter. Meeder Asset Management Inc. now owns 3,403 shares of the biopharmaceutical company’s stock worth $478,000 after buying an additional 2,919 shares in the last quarter. APG Asset Management N.V. grew its position in Alexion Pharmaceuticals by 15.4% during the third quarter. APG Asset Management N.V. now owns 64,532 shares of the biopharmaceutical company’s stock worth $9,053,000 after buying an additional 8,600 shares in the last quarter. Finally, Strs Ohio grew its position in Alexion Pharmaceuticals by 4.6% during the third quarter. Strs Ohio now owns 557,938 shares of the biopharmaceutical company’s stock worth $78,273,000 after buying an additional 24,756 shares in the last quarter. Institutional investors own 95.38% of the company’s stock.

In other news, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the sale, the senior vice president now owns 32,635 shares of the company’s stock, valued at approximately $3,826,780.10. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the sale, the chief executive officer now directly owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,930 shares of company stock valued at $3,378,199. Corporate insiders own 4.35% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $117.10 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10. Alexion Pharmaceuticals, Inc. has a 52 week low of $96.18 and a 52 week high of $149.34. The stock has a market capitalization of $26,346.84, a PE ratio of 59.74, a price-to-earnings-growth ratio of 1.10 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The firm had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the previous year, the company posted $1.26 earnings per share. The company’s revenue was up 9.5% compared to the same quarter last year. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current year.

ALXN has been the subject of several recent analyst reports. Zacks Investment Research cut Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. Robert W. Baird upgraded Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $150.00 target price for the company in a research report on Monday, December 18th. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, UBS Group cut Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Thursday, January 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $152.77.

ILLEGAL ACTIVITY NOTICE: “Eversept Partners LLC Purchases Shares of 33,500 Alexion Pharmaceuticals, Inc. (ALXN)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/02/22/eversept-partners-llc-purchases-shares-of-33500-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply